XSHE
000972
Market cap463mUSD
Oct 09, Last price
4.18CNY
1D
3.98%
1Q
16.76%
Jan 2017
-40.29%
IPO
-4.34%
Name
Chalkis Health Industry Co Ltd
Chart & performance
P/E
—
P/S
6.55
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.24%
Rev. gr., 5y
23.05%
Revenues
492m
+59.70%
Net income
-46m
L-79.97%
CFO
247m
P
Dividend
Jun 10, 20080.03 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chalkis Health Industry Co., Ltd. operates internationally, specializing in the cultivation, processing, and sale of tomatoes. Its diverse product portfolio includes concentrated tomato paste, available in drums and wooden bins; prepared tomato varieties such as peeled, diced, and canned goods; innovative tomato-derived products like fiber sheets and seed oil; and health supplements, specifically lycopene capsules. The company, headquartered in Urumqi, China, adopted its current name, Chalkis Health Industry Co., Ltd., in May 2016, having previously been known as Xinjiang Chalkis Co., Ltd.
Key people
Changjiang Wang
Chairman of the Board · since 2025
Wenbo Mao
General Manager, Director · since 2025
Shanshan Chang
Chief Financial Officer, Deputy General Manager · since 2023
Ye Li
Deputy General Manager · since 2022
Yanxun Zhuang
Deputy General Manager, Director · since 2021
Jiang Xing
Deputy General Manager, Secretary of the Board · since 2023
Juan Li
Director · since 2025
Lijun Sun
Director · since 2024
Kangping Wang
Director · since 2024
Jiadong Yuan
Director · since 2024
Yong Huang
Independent Director · since 2024
Hong Li
Independent Director · since 2024
Xiaogang Wang
Independent Director · since 2024
Headquarters & legal address
治区乌鲁木齐市新疆五家渠25区青湖南路2666号5幢院落室宾馆A院
乌鲁木齐市, XJ 100000
CN
乌鲁木齐市, XJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑00 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||